ANDA 84280, held by Watson Laboratories. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 84280 (Procainamide Hydrochloride), held by Watson Laboratories, was first approved by FDA on Jun 7, 1977, with 15 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 7, 1977 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride500MG · capsule;oral | Procainamide Hydrochloride | Discontinued |
| Jul 29, 1998 | Supplement 47Labeling | Approved | None posted |
| Feb 24, 1992 | Supplement 46Labeling | Approved | None posted |
| Aug 7, 1991 | Supplement 43Manufacturing | Approved | None posted |
| Jan 28, 1991 | Supplement 44Manufacturing | Approved | None posted |
| Nov 1, 1988 | Supplement 40Labeling | Approved | None posted |
| Nov 1, 1988 | Supplement 45Labeling | Approved | None posted |
| Mar 14, 1988 | Supplement 38Manufacturing | Approved | None posted |
| Mar 14, 1988 | Supplement 39Manufacturing | Approved | None posted |
| Dec 18, 1985 | Supplement 33Manufacturing | Approved | None posted |
| Dec 18, 1985 | Supplement 34Manufacturing | Approved | None posted |
| Dec 18, 1985 | Supplement 35Manufacturing | Approved | None posted |
| Jun 3, 1985 | Supplement 31Manufacturing | Approved | None posted |
| Jun 3, 1985 | Supplement 32Manufacturing | Approved | None posted |
| Dec 6, 1983 | Supplement 30Manufacturing | Approved | None posted |
| Jan 24, 1983 | Supplement 29Manufacturing | Approved | None posted |
| Jun 7, 1977 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters